Breathe Well Live Well
Daily Mail |
NHS asthma lifeline: Boost for child victims as rationing watchdog does U-turn
Daily Mail Children with severe asthma are to be given a potentially life-saving drug on the NHS after a U-turn by a health watchdog. The move means youngsters aged six to 11 will be able to benefit from Xolair injections for the first time. Those on a regular … Children as young as six given 'life-changing' asthma drug |
View full post on asthma – Google News
|
NICE U-turn on Novartis' Xolair for asthma
PharmaTimes The National Institute for Health and Clinical Excellence said it now recommends Xolair (omalizumab) as an option for treating severe, persistent allergic asthma in adults, adolescents and children, in a complete turnaround from its earlier intention … Asthma treatment – double U-turn Life-changing jab gives hope to asthma sufferers NICE approves use of asthma drug omalizumab |
View full post on asthma – Google News
|
UK health cost body backs Novartis asthma drug in fresh U-turn
Chicago Tribune LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … Life-changing jab gives hope to asthma sufferers Asthma treatment – double U-turn NICE U-turn on Novartis' Xolair for asthma |
View full post on asthma – Google News
 Yahoo! News (blog) |
NICE backs Novartis asthma drug in fresh U-turn
Yahoo! News (blog) LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … |
View full post on asthma – Google News
 Yahoo! News (blog) |
UK health cost body backs Novartis asthma drug in fresh U-turn
Yahoo! News (blog) LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … U-turn As Asthma Drug Gets Go-ahead NICE U-turn over asthma drug omalizumab |
View full post on asthma – Google News
|
UK health cost body backs Novartis asthma drug in fresh U-turn
Reuters LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … NICE U-turn over asthma drug omalizumab |
View full post on asthma – Google News